{"product_id":"asterdmhealthcare-pestle-analysis","title":"Aster DM Healthcare PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain strategic clarity on Aster DM Healthcare with our concise PESTLE analysis. Explore political, economic, social, technological, legal and environmental forces shaping its growth and risk profile. Ideal for investors and strategists. Purchase the full report for detailed, actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy priorities in GCC and India\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGCC governments have stepped up healthcare capital spending and PPP incentives, shaping reimbursement, capacity expansion and land\/approval access for Aster; policy shifts in UAE, Saudi and Oman frequently redirect patient flows between public and private systems. India's public health spending was about 1.6% of GDP in FY24, influencing reimbursement and scale opportunities. Staying engaged with regulators helps Aster secure pilot programs and preferred-provider status under national health strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance mandates and national schemes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMandatory health insurance rollout across GCC countries (UAE, Saudi Arabia, Qatar, Oman, Bahrain, Kuwait) and India’s Ayushman Bharat PM-JAY (covering about 500 million people with INR 5 lakh per family per year cover) boosts inpatient volumes but compresses prices. Inclusion\/exclusion lists and DRG-like packages determine case-mix profitability, forcing Aster to balance broad participation for scale with selective contracting to protect margins. Rapid changes in benefit design or co-pay rules can materially shift payer mix and EBITDA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and cross-border risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions in the Middle East can sharply reduce patient travel, disrupt supply chains and limit staffing mobility for Aster, which operates across 9 countries; the 2023–24 regional conflicts already curtailed elective referrals and cross-border transfers. Stable periods support elective procedures and medical tourism, while disruptions delay treatments and compress revenue timing. Aster should stress-test procurement and service continuity scenarios and expand insurance and hedging to mitigate event risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorkforce immigration and localization policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWorkforce immigration and localization policies—driven by Saudi Vision 2030 and UAE Emiratisation programs—directly affect Aster DM Healthcare through clinician availability and higher staffing costs as quotas tighten, while streamlined professional licensing (faster DHA\/SQF processing) shortens onboarding time for expatriates.\u003c\/p\u003e\n\u003cp\u003eAster must invest in local training pipelines and credentialing support to mitigate wage inflation and regulatory risk, and maintain a strategic mix of expatriate and local clinicians to reduce exposure to nationalization mandates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eregulatory drivers: nationalization policies (Vision 2030, Emiratisation)\u003c\/li\u003e\n\u003cli\u003eoperational impact: onboarding speed up with streamlined licensing\u003c\/li\u003e\n\u003cli\u003ecost risk: tighter quotas → upward wage pressure\u003c\/li\u003e\n\u003cli\u003emitigation: local training + balanced expatriate\/local staffing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-private partnership (PPP) and accreditation pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to PPP tenders allows Aster DM Healthcare to expand beds and diagnostics with lower capex across India and GCC; early wins secure long-term operating contracts and scale. Accreditation standards such as JCI (over 2,800 accredited facilities globally) and national bodies determine eligibility and reputation; Aster’s compliance focus enhances bid competitiveness. Policy shifts toward performance-linked payments can compress near-term cash flows if tighter KPIs are enforced.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePPP access: lower capex, faster footprint\u003c\/li\u003e\n\u003cli\u003eAccreditation: JCI\/national eligibility and reputation\u003c\/li\u003e\n\u003cli\u003eAster advantage: early participation, compliance excellence\u003c\/li\u003e\n\u003cli\u003eRisk: performance-linked payments may affect cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGCC capex+PPPs shift access; India \u003cstrong\u003e~1.6%\u003c\/strong\u003e GDP; insur \u003cstrong\u003e~500m\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernments' higher GCC health capex and PPPs reshape reimbursement and access; India's public health spend was ~1.6% of GDP in FY24 and Ayushman Bharat covers ~500m people. Nationalization (Vision 2030, Emiratisation) raises staffing costs; 2023–24 regional conflicts cut medical tourism and referrals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic spend\u003c\/td\u003e\n\u003ctd\u003eIndia 1.6% FY24\u003c\/td\u003e\n\u003ctd\u003eReimbursement pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsurance\u003c\/td\u003e\n\u003ctd\u003eAyushman Bharat ~500m\u003c\/td\u003e\n\u003ctd\u003eVolume up, prices down\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003eVision 2030\/Emiratisation\u003c\/td\u003e\n\u003ctd\u003eWage inflation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Aster DM Healthcare across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed insights and trend analysis; designed for executives and investors to identify risks, opportunities, and forward-looking scenarios to inform strategy, funding pitches, and operational planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Aster DM Healthcare for quick sharing or slide-ready use, easily editable for regional or business-line notes and ideal for rapid alignment across teams during planning sessions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic growth and disposable income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGCC GDP growth, buoyed by oil, ran about 3–5% in 2024 while India expanded roughly 6–7% in 2024–25 (IMF), driving stronger demand for elective and premium healthcare. Slowdowns shift patient mix toward essential, price-sensitive care and compress ARPU. Aster can flex capacity, service tiers and pricing to protect occupancy and margins. Regional diversification across GCC and India smooths revenue cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOil prices and fiscal dynamics in the Gulf\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigher oil prices (Brent averaged about $86\/bbl in 2024) typically expand GCC public spending and insurance coverage, while IMF-estimated fiscal breakevens clustered roughly $70–90\/bbl in 2024. Downturns can delay payer reimbursements and push PPP timelines out, so Aster should pace capex to fiscal signals and maintain cash buffers covering 6–12 months of receivables to reduce exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and inflation pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGCC USD-pegged currencies provide import price stability for Aster’s Middle East operations, while India faces INR volatility (around 82–85 per USD in mid‑2024) that can swing local costs. Medical consumables and equipment inflation—pressures seen globally in 2023–24—can compress margins. Aster can mitigate via group procurement, FX hedging and contract price escalators. Local sourcing and standardized formularies further control costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance penetration and payer mix evolution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising private insurance adoption in India alongside Ayushman Bharat covering about 500 million people and widespread employer-backed plans in GCC markets (UAE expatriates ~88%) expands covered lives for Aster, but tighter payer utilization management is already capping length of stay and reimbursement rates. Aster must strengthen revenue-cycle management and case-mix optimization to protect margins amid growing utilization controls. Early value-based care pilots in India and GCC could reward outcomes and efficiency, shifting incentives toward bundled payments and quality metrics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCovered lives: Ayushman Bharat ~500 million; GCC employer-covered expatriate base high (~UAE 88% expats)\u003c\/li\u003e\n\u003cli\u003eRisk: payer utilization management reducing LOS and per-case reimbursement\u003c\/li\u003e\n\u003cli\u003ePriority: improve revenue-cycle management, coding, case-mix and DRG-like pricing\u003c\/li\u003e\n\u003cli\u003eOpportunity: value-based pilots may enable bundled payments and outcome-linked premiums\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical tourism flows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegional hubs draw specialty patients from Africa and South Asia, and Aster DM Healthcare, with 350+ facilities across 10+ countries, is positioned to capture this flow. Currency differentials and travel costs materially affect inbound volumes, while Aster can bundle cross-border care with teleconsult pre\/post follow-ups to boost retention. Geopolitical or pandemic restrictions remain material downside risks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegional hubs: patients from Africa\/South Asia\u003c\/li\u003e\n\u003cli\u003eScale: 350+ facilities, 10+ countries (2024)\u003c\/li\u003e\n\u003cli\u003eService mix: cross-border packages + teleconsults\u003c\/li\u003e\n\u003cli\u003eRisks: geopolitical\/pandemic travel curbs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGCC capex+PPPs shift access; India \u003cstrong\u003e~1.6%\u003c\/strong\u003e GDP; insur \u003cstrong\u003e~500m\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGCC GDP ~3–5% (2024) and India ~6–7% (2024–25) boost elective demand; Brent ~86$\/bbl (2024) lifts GCC spend while INR ~82–85\/USD (mid‑2024) risks costs. Aster (350+ facilities, 10+ countries, 2024) should flex capacity, hedge FX, and hold 6–12 months receivables; rising private insurance and Ayushman Bharat (~500M) expand covered lives but tighten utilization.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGCC GDP\u003c\/td\u003e\n\u003ctd\u003e3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia GDP\u003c\/td\u003e\n\u003ctd\u003e6–7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent\u003c\/td\u003e\n\u003ctd\u003e$86\/bbl avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINR\u003c\/td\u003e\n\u003ctd\u003e82–85\/USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAster scale\u003c\/td\u003e\n\u003ctd\u003e350+ facilities, 10+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAyushman Bharat\u003c\/td\u003e\n\u003ctd\u003e~500M covered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAster DM Healthcare PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe Aster DM Healthcare PESTLE Analysis preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. The content, layout, and structure visible are the final version with no placeholders or edits needed. After checkout you’ll instantly download this identical, professionally structured file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675725480313,"sku":"asterdmhealthcare-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/asterdmhealthcare-pestle-analysis.png?v=1755809933","url":"https:\/\/portersfiveforce.com\/products\/asterdmhealthcare-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}